TrialCurveLUSTRE: reconstructed Kaplan–Meier curves
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | JAMA Oncol. 2024 Sep 19;10(11):1571–5. doi: 10.1001/jamaoncol.2024.3089 |
|---|---|
| DOI | 10.1001/jamaoncol.2024.3089 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Local control
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: SBRT not reached; CRT not reached. Survival at 18 months: SBRT 92%; CRT 89%. Hazard ratio SBRT vs CRT 0.61 (95% CI 0.31–1.21).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| SBRT | 154 | 18 | not reached |
| CRT | 79 | 16 | not reached |
- SBRT vs CRT: reconstructed HR 0.61 (95% CI 0.31–1.21)
Landmark survival (reconstructed)
| Time | SBRT | CRT |
|---|---|---|
| 6 mo | 98.0% | 100.0% |
| 12 mo | 94.4% | 95.9% |
| 18 mo | 92.2% | 88.8% |
| 24 mo | 89.6% | 84.5% |
| 36 mo | 87.6% | 81.1% |
| 48 mo | 84.5% | 78.6% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.61, reconstructed 0.614 pass
Event-free survival
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: CRT 33.1 months; SBRT 33.0 months. Survival at 18 months: CRT 71%; SBRT 66%. Hazard ratio CRT vs SBRT 0.98 (95% CI 0.69–1.38).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| CRT | 79 | 50 | 33.1 |
| SBRT | 153 | 90 | 33.0 |
- CRT vs SBRT: reconstructed HR 0.98 (95% CI 0.69–1.38)
Landmark survival (reconstructed)
| Time | CRT | SBRT |
|---|---|---|
| 6 mo | 97.5% | 86.9% |
| 12 mo | 79.7% | 75.6% |
| 18 mo | 70.9% | 65.7% |
| 24 mo | 63.3% | 60.3% |
| 36 mo | 47.3% | 49.0% |
| 48 mo | 39.5% | 40.0% |
| 60 mo | 31.9% | 33.3% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.02, reconstructed 1.02 pass
Overall survival
From figure panel D · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: CRT 55.6 months; SBRT 52.6 months. Survival at 18 months: CRT 87%; SBRT 79%. Hazard ratio CRT vs SBRT 0.87 (95% CI 0.59–1.29).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| CRT | 79 | 38 | 55.6 |
| SBRT | 154 | 73 | 52.6 |
- CRT vs SBRT: reconstructed HR 0.87 (95% CI 0.59–1.29)
Landmark survival (reconstructed)
| Time | CRT | SBRT |
|---|---|---|
| 6 mo | 98.7% | 96.1% |
| 12 mo | 92.4% | 90.8% |
| 18 mo | 87.3% | 79.4% |
| 24 mo | 87.3% | 76.0% |
| 36 mo | 69.6% | 63.2% |
| 48 mo | 55.1% | 52.7% |
| 60 mo | 39.6% | 41.7% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.18, reconstructed 1.15 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/lustre-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/lustre-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: JAMA Oncol. 2024 Sep 19;10(11):1571–5. doi: 10.1001/jamaoncol.2024.3089 doi:10.1001/jamaoncol.2024.3089. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/lustre
Report a problem with these data
Related trials
- PRESERVE-003: Overall survival (OS); Progression-free survival (PFS, investigator assessment)
- CA209-7AL: Progression-free survival
- QUARTZ: Overall survival from randomisation
- KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
- PIN: Overall survival
- Rezivertinib in EGFR-mutated NSCLC with CNS metastases: CNS progression-free survival (BICR)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials